Chimovits Erez — SEC insider filings
SEC reporting owner CIK 1706399. 15 insider filings on record with FilingPulse; latest filed 2026-09-30.
Transaction summary — filings shown
Covers all 15 filings on record, filed 2020-09-17 to 2026-09-30. Counts and totals are arithmetic on values as filed — descriptive data, not a recommendation.
- Open-market purchases (code P, non-derivative): 13 legs across 6 filings — 5,530,998 shares, $60,793,674 total (shares × price as filed).
- Open-market sales (code S, non-derivative): 1 leg across 1 filing — 24,344 shares, $9,280 total (shares × price as filed).
- Other reported legs (grants, option exercises, tax withholding, gifts, derivative-security transactions, …): 30.
- Largest priced transaction: purchase of 1,666,667 shares @ $18.00 ($30,000,006) in Braveheart Bio, Inc., filed 2026-08-11.
By issuer — same filings
Open-market purchase/sale legs on non-derivative securities, grouped by issuer. Role is as filed on the newest filing for that issuer. Dollar totals cover priced legs only (shares × price as filed). Ordered by priced transaction value, largest first.
| Issuer | Role (as filed) | Filings | Purchases (P) | Sales (S) | Other legs |
|---|---|---|---|---|---|
| Braveheart Bio, Inc. (BRVE) | Director, 10% owner | 2 | 2 legs · 1,940,000 sh · $34,920,000 | — | 3 |
| Upstream Bio, Inc. (UPB) | Director | 4 | 2 legs · 825,000 sh · $14,025,000 | — | 9 |
| LogicBio Therapeutics, Inc. (LOGC) | Director, 10% owner | 1 | 3 legs · 1,481,482 sh · $8,888,892 | — | — |
| Adicet Bio, Inc. (ACET) | Director, 10% owner | 3 | 4 legs · 875,000 sh · $1,828,750 | — | 5 |
| ADARx Pharmaceuticals, Inc. (ADRX) | Director | 2 | 1 leg · 61,516 sh · $1,045,772 | — | 8 |
| BiomX Inc. (PHGE) | 10% owner | 3 | 1 leg · 348,000 sh · $85,260 | 1 leg · 24,344 sh · $9,280 | 5 |
Insider filings — Chimovits Erez
| Filed | Form | Issuer | Reported transactions | Source |
|---|---|---|---|---|
| 2026-09-30 | 4 | ADARx Pharmaceuticals, Inc. (ADRX) | Conversion (C): 7,127,019 · Conversion (C): 1,333,975 · Conversion (C): 513,067 · Conversion (C): 256,448 · Purchase (P): 61,516 @ $17 · Conversion (C): 7,127,019 (derivative) @ $0 · +3 more | EDGAR |
| 2026-09-24 | 3 | ADARx Pharmaceuticals, Inc. (ADRX) | Holdings only — no transactions reported | EDGAR |
| 2026-08-11 | 4 | Braveheart Bio, Inc. (BRVE) | Conversion (C): 9,132,420 · Purchase (P): 1,666,667 @ $18 · Purchase (P): 273,333 @ $18 · Conversion (C): 40,000,000 (derivative) @ $0 | EDGAR |
| 2026-08-07 | 4 | Braveheart Bio, Inc. (BRVE) | Grant/award (A): 30,000 (derivative) @ $0 | EDGAR |
| 2026-06-11 | 4 | Upstream Bio, Inc. (UPB) | Grant/award (A): 17,096 (derivative) @ $0 | EDGAR |
| 2025-06-12 | 4 | Upstream Bio, Inc. (UPB) | Grant/award (A): 17,096 (derivative) @ $0 | EDGAR |
| 2024-10-17 | 4 | Upstream Bio, Inc. (UPB) | Conversion (C): 721,956 · Purchase (P): 165,000 @ $17 · Conversion (C): 2,887,833 · Purchase (P): 660,000 @ $17 · Conversion (C): 524,500 (derivative) · Conversion (C): 2,098,000 (derivative) · +2 more | EDGAR |
| 2024-10-15 | 4 | Upstream Bio, Inc. (UPB) | Grant/award (A): 17,096 (derivative) @ $0 | EDGAR |
| 2024-05-20 | 4 | BiomX Inc. (PHGE) jointly with OrbiMed Israel BioFund GP Limited Partnership, OrbiMed Israel GP Ltd., GORDON CARL L | Option exercise/expiry (X): 9,280,408 @ $0.24 · Sale (S): 24,344 @ $0.38 · Option exercise/expiry (X): 9,280,408 (derivative) @ $0 | EDGAR |
| 2024-03-19 | 4 | BiomX Inc. (PHGE) jointly with OrbiMed Israel BioFund GP Limited Partnership, OrbiMed Israel GP Ltd., GORDON CARL L | Purchase (P): 4,327 (derivative) · Purchase (P): 2,163,500 (derivative) | EDGAR |
| 2023-06-29 | 4 | Adicet Bio, Inc. (ACET) jointly with ORBIMED ADVISORS LLC, OrbiMed Capital GP V LLC, OrbiMed Capital GP VI LLC, OrbiMed Genesis GP LLC, OrbiMed Advisors Israel II Ltd, OrbiMed Israel GP II, L.P., OrbiMed Israel GP Ltd., OrbiMed Israel BioFund GP Limited Partnership | Purchase (P): 125,000 @ $2.09 · Purchase (P): 250,000 @ $2.09 · Purchase (P): 442,000 @ $2.09 · Purchase (P): 58,000 @ $2.09 | EDGAR |
| 2023-03-17 | 4 | BiomX Inc. (PHGE) jointly with OrbiMed Israel BioFund GP Limited Partnership, OrbiMed Israel GP Ltd., GORDON CARL L | Purchase (P): 348,000 @ $0.24 · Purchase (P): 1,789,959 (derivative) | EDGAR |
| 2021-02-18 | 4 | Adicet Bio, Inc. (ACET) | Grant/award (A): 420,299 @ $13 · Grant/award (A): 104,050 @ $13 | EDGAR |
| 2020-10-05 | 4 | LogicBio Therapeutics, Inc. (LOGC) | Purchase (P): 545,974 @ $6 · Purchase (P): 639,212 @ $6 · Purchase (P): 296,296 @ $6 | EDGAR |
| 2020-09-17 | 4 | Adicet Bio, Inc. (ACET) | Grant/award (A): 902,885 · Grant/award (A): 292,607 · Grant/award (A): 30,000 (derivative) @ $0 | EDGAR |
FilingPulse's Form 4 archive currently extends back to 2020-09-16 and is expanding backward through EDGAR history; Forms 3 and 5 are covered live-forward since 2026-09-23 (no 3/5 history). Earlier filings by this insider may not be indexed yet. Names and roles are shown as filed.
GET https://api.filingpulse.io/v1/insider-trades?owner_cik=1706399 returns every filing on this page — normalized, with footnotes and derivative legs — and webhooks push new filings to you in seconds. Get a free API key → · API docs